Thus, morphologically grade 3 meningiomas demonstrating loss of p16 expression may be considered for further investigation as part of ongoing trials using cell cycle inhibitors such as ribociclib (NCT02933736) and abemaciclib (NCT02523014, NCT03220646). The gene discussed is CDKN2A; the disease is meningioma.